Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/205363
Title: | Adjuvant dabrafenib and trametinib for patients with resected BRAF-mutated melanoma: DESCRIBE-AD real-world retrospective observational study |
Author: | Manzano, José L. Martin Liberal, Juan Fernández Morales, Luis A. Benítez, Gretel Medina Martínez, Javier Quindós, María García Castaño, Almudena Fernández, Ovidio Simo, Rocío V. Majem, Margarita Bellido, Lorena Ayala de Miguel, Pablo Campos Bonilla, Begoña Espinosa, Enrique Macías Cerrolaza, José A. Gil Arnaiz, Irene Lorente, David Rodriguez Lescure, Alvaro Perez, Victor N. López Castro, Rafael Gramaje, María G. Puértolas, Teresa Rodriguez Moreno, Juan F. Espasa Font, Laia Belaustegui Ferrández, Guillermo Cerezuela Fuentes, Pablo |
Keywords: | Tractament adjuvant del càncer Melanoma Adjuvant treatment of cancer Melanoma |
Issue Date: | 28-Mar-2023 |
Publisher: | Ovid Technologies (Wolters Kluwer Health) |
Abstract: | BRAF and MEK inhibitor, dabrafenib plus trametinib, adjuvant therapy is effective for high-risk resected melanoma patients with BRAF-V600 mutations. However, real-world evidence is limited. We aimed to determine the feasibility of this therapy in routine clinical practice. DESCRIBE-AD, a retrospective observational study, collected real-world data from 25 hospitals in Spain. Histologically confirmed and resected BRAF-mutated melanoma patients aged & GE;18 years who were previously treated with dabrafenib plus trametinib adjuvant therapy, were included. The primary objectives were treatment discontinuation rate and time to discontinuation. The secondary objectives included safety and efficacy. From October 2020 to March 2021, 65 patients were included. Dabrafenib and trametinib discontinuation rate due to treatment-related adverse events (TRAEs) of any grade was 9%. Other reasons for discontinuation included patients' decisions (6%), physician decisions (6%), unrelated adverse events (3%), disease progression (5%), and others (5%). The median time to treatment discontinuation was 9 months [95% confidence interval (CI), 5-11]. G3-4 TRAEs occurred in 21.5% of patients, the most common being pyrexia (3%), asthenia (3%), and diarrhoea (3%). Unscheduled hospitalisations and clinical tests occurred in 6 and 22% of patients, respectively. After 20-month median follow-up (95% CI, 18-22), 9% of patients had exitus due to disease progression, with a 12-month relapse-free survival and overall survival rates of 95.3% and 100%, respectively. Dabrafenib and trametinib adjuvant therapy proved effective for melanoma patients in a real-world setting, with a manageable toxicity profile. Toxicity frequencies were low leading to low incidence of unscheduled medical visits, tests, and treatment discontinuations. |
Note: | Reproducció del document publicat a: https://doi.org/10.1097/CMR.0000000000000888 |
It is part of: | Melanoma Research, 2023, vol. 33, num. 5, p. 388-397 |
URI: | http://hdl.handle.net/2445/205363 |
Related resource: | https://doi.org/10.1097/CMR.0000000000000888 |
ISSN: | 0960-8931 |
Appears in Collections: | Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL)) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
adjuvant_dabrafenib_and_trametinib_for_patients.5.pdf | 902.16 kB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License